Neurocrine biosciences reports positive phase ii data for crinecerfont in adults with congenital adrenal hyperplasia at endo online 2020

Neurocrine biosciences inc - reports positive phase ii data for crinecerfont in adults with congenital adrenal hyperplasia at endo online 2020.neurocrine biosciences inc - initiation of global registrational study of crinecerfont in adults planned for h2 2020.neurocrine biosciences inc - crinecerfont demonstrates meaningful reductions in key disease biomarkers after 14 days of treatment.
NBIX Ratings Summary
NBIX Quant Ranking